Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome

Osteoporosis International

Volumn 24, Issue 8, 2013, Pages 2191-2199

  Belaya, Z E ^a   Rozhinskaya, L Y ^a   Melnichenko, G A ^a   Solodovnikov, A G ^b   Dragunova, N V ^a   Iljin, A V ^a   Dzeranova, L K ^a   Dedov, I I ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b URAL STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Cushing's syndrome; Dickkopf 1; Glucocorticoid induced osteoporosis; Sclerostin; Secreted frizzled related protein 1

Indexed keywords

BETA CATENIN; CARBOXY TERMINAL TELOPEPTIDE; DICKKOPF 1 PROTEIN; HYDROCORTISONE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 1; WNT PROTEIN;

ADULT; AGE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; DOWN REGULATION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; MALE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX; WNT SIGNALING PATHWAY;

ADULT; BIOLOGICAL MARKERS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; CUSHING SYNDROME; FEMALE; FEMUR NECK; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUMBAR VERTEBRAE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OSTEOGENESIS; OSTEOPOROTIC FRACTURES; OSTEOPROTEGERIN; RANK LIGAND; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 84880252637     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2268-y     Document Type: Article

References (45)

1. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticoids and risk of fractures. J Bone Miner Res 15:933-1000
2. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893-899
3. Cushing H (1932) The basofil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 50:137-195
4. Tauchmanova L, Pivonello R, Di Somma C, Rossi R, De Martino MC, Camera L, Klain M, Salvatore M, Lombardi G, Colao A (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 91:1779-1784
5. Vestergaard P, Lindholm J, Jorgensen JOI, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Kristensen L, Feldt-Rasmussen U, Mosekilde L (2002) Increased risk of osteoporotic fractures in patients with Cushing's syndrome. Eur J Endocrinol 146:51-56
6. Nieman LK, Biller BMK, Finding JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526-1540
7. Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328
8. Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorene R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE, Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257-2276
9. Lukert BP, Higgins JC, Stoskopf MM (1986) Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J Clin Endocrinol Metab 62:1056-1058
10. Szappanos A, Toke J, Lippai D, Patocs A, Igaz P, Szucs N, Futo L, Glaz E, Racz K, Toth M (2010) Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment. Osteoporos Int 21:637-645
11. Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol 154:109-118
12. Kaltsas G, Makras P (2010) Skeletal diseases in Cushing's syndrome: osteoporosis versus arthropathy. Neuroendocrinology 92(supp 1):60-64
13. Wang F-S, Lin C-L, Chen Y-J, Wang C-J, Yang KD, Huang Y-T, Sun Y-C, Huang H-C (2005) Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. J Endocrinol 146:2415-2423
14. Wang F-S, Ko J-Y, Yeh D-W, Ke H-C, Wu H-L (2008) Modulation of dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation and bone mass loss. Endocrinology 149:1793-1801
15. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE (2008) Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis. Arthritis Rheum 58:1674-1686
16. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK (2011) Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 63:2385-2395
17. Belaya ZE, Iljin AV, Melnichenko GA, Rozhinskaya LY, Dragunova NV, Dzeranova LK, Butrova SA, Troshina EA, Dedov II (2012) Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing's syndrome. Endocrine 41:494-500
18. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM, AACE Osteoporosis Task Force (2010) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(Supp 3):1-37
19. Ardawi M-S M, Al-Kadi HA, Rouzi AA, Qari MH (2011) Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 26:2812-2822
20. Modder UIL, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S (2011) Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 26:27-34
21. Kirmani S, Amin S, McCready LK, Atkinson EJ, Melton LJ 3rd, Muller R, Khosla S (2012) Sclerostin levels during growth in children. Osteoporos Int 23:1123-1130
22. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Beatrice Franci M, Campagna MS, Calabro A, Cataldo D, Stolakis K, Dotta F, Nuti R (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrin Metab 97:1737-1744
23. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E (2012) Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women - the six-month effect of risedronate and teriparatide. Osteoporos Int 23:1171-1176
24. Genant HK, Wu CY, van Kujik C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148
25. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PMM (2003) The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 56:1129-1135
26. Faul F, Erdfelder E, Lang A, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical science. Behav Res Methods 39:175-191
27. Wajchenberg BL, Liberman B, Giannella Neto D, Morozimato MY, Semer M, Bracco LO, Saligado LR, Knoepfelmacher M, Borges MH, Pinto AC, Kater CE, Lengyel AM (1996) Growth hormone axis in Cushing's syndrome. Horm Res 45:99-107
28. van Lierop AH, van Eerden AW, Hamdy NAT, Hermus AR, den Heijer M, Papapolous SE (2012) Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab. doi: 10.1210/jc.2012-2218, first published ahead of print July 27
29. Sereg M, Toke J, Patocs A, Varga I, Igaz P, Szucs N, Horanyi J, Pusztai P, Czirjak S, Glaz E, Racz K, Toth M (2011) Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing's syndrome. Steroids 76:38-42
30. Belaya ZE, Dragunova NV, Iljin AV, Rozhinskaya LY, Melnichenko GA (2012) Bone metabolism marker as a diagnostic test for endogenous hypercorticism. J Osteoporos Int 23(supp 2):S173-S174
31. Poole KES, Bezooijen RL, Loverridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB 19:1842-1844
32. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready L, Oursler MJ, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056-5062
33. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248-2253
34. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney JJ, Lazaretti-Castro M, Silverberg SJ, Bilezikian JP (2012) Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 97:1737-1744
35. Yamaguchi T, Sugimoto T (2011) Bone metabolism and fracture risk in type 2 diabetes mellitus. Endocr J 58:613-624
36. Wu CH, Liou TH, Hsiao PL, Lin YC, Chang KH (2011) Contribution of ischemic stroke to hip fracture risk and the influence of gender difference. Arch Phys Med Rehabill 92:1987-1991
37. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ (2012) Update on Wnt signaling in bone cell biology and bone diseases. J Gene 341:19-39
38. Swanson C, Lorentzon M, Conaway HH, Lerner UH (2006) Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB in mouse calvarial bones. Endocrinology 147:3613-3622
39. Camozzi V, Sanguin F, Albigier N, Scaroni C, Mantero F, Zaninotto M, Frigo A, Piccolo M, Luisetto G (2010) Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome. Eur Endocrinol 162:85-90
40. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P (2001) Increased serum osteoprotegerin in disorders characterized by persistent immune activation of glucocorticoid excess - possible role in bone homeostasis. Eur Endocrinol 145:685-690
41. Dovio A, Allasino B, Palmas E, Ventura M, Pia A, Saba L, Aroasio E, Terzolo M, Angeli A (2007) Increased osteoprotegerin levels in Cushing's syndrome are associated with an adverse cardiovascular risk profile. J Clin Endocrin Metab 92:1803-1808
42. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Olivera-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323
43. Sinningen K, Tsourdi E, Rauner M, Rachner TD, Hamann C, Hofbauer LC (2012) Skeletal and extraskeletal actions of denosumab. Endocrine 42:52-62
44. Pivonello R, Melnichenko G, Zacharieva S, Gu F, Oscar B, Shah NS, Gaillard R, Colao A (2011) Mission study: an international observational study on the mortality in Cushing's syndrome. Endocr Abstr 26:32
45. Psaras T, Milian M, Hattermann V, Freiman T, Gallwitz B, Honegger J (2011) Demographic factors and the presence of comorbidities do not promote early detection of Cushing's disease and acromegaly. Exp Clin Endocrinol Diabetes 119:21-25